Pfizer’s Outlook Improves
Having spent $5 billion on research and development in 2002, Pfizer (NYSE: PFE) is king of the drug world. And with its $60 billion Pharmacia merger completed in April, the king just got fatter
Pfizer’s Outlook Improves
Having spent $5 billion on research and development in 2002, Pfizer (NYSE: PFE) is king of the drug world. And with its $60 billion Pharmacia merger completed in April, the king just got fatter